CERo Therapeutics Holdings, Inc. Common Stock (CERO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CERo Therapeutics Holdings, Inc. Common Stock (CERO) has a cash flow conversion efficiency ratio of 0.298x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.76 Million) by net assets ($-9.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is CERo Therapeutics Holdings, Inc. Common 's balance sheet to measure how much of total assets are equity-financed.
CERo Therapeutics Holdings, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how CERo Therapeutics Holdings, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of CERo Therapeutics Holdings, Inc. Common to evaluate the quality of earnings relative to operating cash generation.
CERo Therapeutics Holdings, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CERo Therapeutics Holdings, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
in Style Group PLC
LSE:ITS
|
-0.054x |
|
finnCap Group PLC
LSE:CAV
|
0.017x |
|
Medivie Therapeutic Ltd
TA:MDVI
|
0.217x |
|
New Destiny Mining Corp
V:NED
|
0.006x |
|
Quintegra Solutions Limited
NSE:QUINTEGRA
|
0.000x |
|
Time Out Group plc
LSE:TMO
|
-0.052x |
|
Hill Street Beverage Company Inc
V:HILL
|
-0.272x |
|
Dewata Freight International Tbk PT
JK:DEAL
|
0.041x |
Annual Cash Flow Conversion Efficiency for CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market value of CERo Therapeutics Holdings, Inc. Common .
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-5.45 Million | $-16.08 Million | 2.952x | -3.39% |
| 2024-12-31 | $-1.89 Million | $-5.79 Million | 3.056x | +2119.92% |
| 2023-12-31 | $-42.06 Million | $-5.79 Million | 0.138x | +131.12% |
| 2022-12-31 | $2.47 Million | $-1.09 Million | -0.442x | -10742.21% |
| 2021-12-31 | $170.83 Million | $-697.11K | -0.004x | -- |
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.